SANTOMERO ANTHONY M
Known title: DirectorCIK: 0001432225
Associated companies
Transaction History
| RNR | ▲ Buy | Grant | 759 | $0 | 3/1/2023 | View on chart |
| RNR | ▲ Buy | Grant | 1,065 | $0 | 3/1/2022 | View on chart |
| RNR | ▲ Buy | Grant | 759 | $0 | 3/1/2023 | View on chart |
| RNR | ▲ Buy | Grant | 1,065 | $0 | 3/1/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
RenaissanceRe Q2 2026 Earnings Call Highlights Discounted Valuation
During the Q2 2026 earnings call, RenaissanceRe reiterated its diversified reinsurance strategy and maintained a cautious outlook. Analysts noted the stock trades at a discount to peers, with a 142% run and a P/E of 5.2, suggesting potential undervaluation. The company’s dividend yield of 0.69% and analyst target of $346.40 contrast with its current price near the 52‑week low of $231.17. RSI sits at 45.5 and the support level at $292.90 adds context to its valuation debate.
RenaissanceRe Q2 2026 Earnings Call Highlights Discounted Valuation. During the Q2 2026 earnings call, RenaissanceRe reiterated its diversified reinsurance strategy and maintained a cautious outlook. Analysts noted the stock trades at a discount to peers, with a 142% run and a P/E of 5.2, suggesting potential undervaluation. The company’s dividend yield of 0.69% and analyst target of $346.40 contrast with its current price near the 52‑week low of $231.17. RSI sits at 45.5 and the support level at $292.90 adds context to its valuation debate.